Jinjie Wu

发表

Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases

D. Zang, Jinbao Liu, Xiaofen Li, 2017, Oncotarget.

Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase

Xiaolan Zhang, Jinbao Liu, Zhiming He, 2018, BioMetals.

CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.

Nandan Wu, C. Du, Jinjie Wu, 2022, Cancer letters.

Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

D. Zang, Jinbao Liu, Xiaofen Li, 2015, Oncotarget.

Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation

D. Zang, Jinbao Liu, Hongbiao Huang, 2017, Cell Death & Disease.

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms

D. Zang, Jinbao Liu, B. Carter, 2016, Journal of Hematology & Oncology.

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy

D. Zang, Jinbao Liu, Zhiming He, 2016, Biochemical pharmacology.

A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy

D. Zang, Q. Dou, Jinbao Liu, 2016, Oncogene.